Chinese authorities have issued guidelines recommending Roche’s anti-inflammation drug Actemra to combat severe complications caused by the COVID-19 coronavirus.
AbbVie and Roche's Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial that was supposed to confirm its efficacy.
England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with a form of advanced lymphoma, NICE has said in first draft g
Roche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the FDA agreed to a fast review of Tecentriq monotherapy, preventing the n